Pepti Review: NAD+ in Three Routes, Including One You Swallow

Pepti (hellopepti.com) sells NAD+ three ways and publishes a price for each: $179 a month for the injection, $219 for the nasal spray, $159 for a capsule.¹ Every figure is flat — the same monthly price at every dose — and cancelable at the end of a cycle with no minimum term. Among the six operators we read in August 2026, it is the only one offering all three routes at once, which makes it the cleanest place to see something this category keeps blurring.

The capsule is the reason this review exists.

The three rungs

We pulled these from the site's own JavaScript bundle rather than from a marketing page, because Pepti renders as a single-page app and its catalog lives in the code. Where Pepti publishes both a subscription price and a one-time price for an item, the one-time figure is the monthly one times 1.25 — we checked that on four separate products and it held each time. It does not publish a one-time figure for any of the three NAD+ rungs, so neither do we.

The nasal rung is the dearest of the three, which is worth flagging because it is also the dearest nasal NAD+ we track — Auren Rx's four nasal options run $169 to $249 depending on strength and bottle size, and Pepti's single $219 spray is quoted without a strength or a volume attached to it anywhere we could find. You cannot work out what a milliliter costs, so you cannot compare it to anything.

The capsule is not the oral route the trials studied

This is the part a product page will not tell you, and it is the single most useful thing on this page.

When this site says the oral route has human data behind it, it means the precursors. Nicotinamide riboside is orally bioavailable and raises blood NAD+ in people, reliably and dose-dependently.²³ Oral NMN does the same in controlled trials.⁴⁵ Those molecules are small, they survive the gut, and there is a published pharmacokinetic record showing what happens after you swallow them.

A capsule of NAD+ itself is a different proposition. NAD+ is a dinucleotide of about 663 Daltons,⁶ and we could find no published human pharmacokinetic study of swallowing it intact — not for Pepti's capsule and not for anyone else's. The oral NAD+ literature people cite is precursor literature. The two get sold under the same word.

So the $159 capsule is not a cheaper way to get the thing the trials tested. It is a third unmeasured route sitting next to two other unmeasured routes, and the fact that it costs less than the injection tells you about a price list rather than about absorption. Our route-by-route breakdown works through why the bioavailability ranking people repeat does not survive contact with the outcome data.

What stands behind the other two routes

Nothing you have not read here before, and it is worth being exact.

For injected NAD+, there is no randomized human trial and no published pharmacokinetic study. The one human study of administered NAD+ is a small pilot using a six-hour intravenous infusion, and it measured the plasma and urine metabolome rather than any clinical outcome.⁷ Injection is not IV, and the IV literature stops there. The injection evidence file has the full account.

For intranasal NAD+, the supporting studies are rodent models of stroke and traumatic brain injury.⁸⁹ They are real experiments and they are not evidence that a spray raises NAD+ in a healthy adult; nose-to-brain delivery remains an open research problem rather than a solved one.¹⁰ See can it absorb through the nose.

Even where the biomarker does move, the outcomes are the weak part: a systematic review of precursor trials found metabolic effects limited and inconsistent despite NAD+ rising.¹¹ Three routes at three prices is a wider menu, not a stronger case.

The catalog is enormous, and that is a finding

Sixty-eight prescription items, extracted from the bundle. NAD+ sits inside a shelf that also carries semaglutide, tirzepatide, BPC-157, sermorelin, tesamorelin, epithalon, MOTS-c, SS-31, PT-141, semax, selank, synapsin, methylene blue, oxytocin, kisspeptin, estradiol, clomiphene, hydroquinone and at-home blood panels.

Three of those items should be named plainly, because a reader arriving for NAD+ will see them in the same navigation: retatrutide, melanotan II and IGF-1 LR3. Retatrutide has no FDA approval in any form or jurisdiction. None of the three is something this publication would put in front of a reader as a recommendable option, and their presence on a menu is a fact about the operator's judgment, not a footnote.

The company is explicit that it does not sell research-use-only compounds and that everything is prescribed by a licensed clinician. That is a meaningful distinction from the gray-market peptide sellers this brand name sits close to. It is not the same as a short catalog.

What the site contradicts about itself

Three, and they matter in different ways.

Where it operates. Four separate surfaces — a shipping page, a state-availability page, a providers page and the homepage title — say 36 states, and the list is published. The terms of service say the services are available in 50. Four corroborating surfaces beat one line in a legal document, so we treat 36 as the real number, but you should check your own state on the published list rather than on the terms.

When you are charged. The how-it-works page says you pay nothing until a physician approves your treatment. The refund policy says payment is collected at checkout, before the provider reviews your intake. The refund policy governs, so assume you are charged first and refunded if you are declined — five to ten business days, per the same document.

A price ladder that renders nowhere. Pepti's GLP-1 pages ship a per-dose price array in their production data — roughly three times the flat headline — that no component on the site consumes. We could not reach a checkout to break the tie, because the checkout endpoint accepts no GET request. This is a weight-loss artifact rather than a NAD+ one, and we record it here anyway: a published price and a charged price are the same thing only until they are not, and this is a site where a second set of numbers is demonstrably sitting in production.

Who is behind it

No pharmacy is named. The site describes independent FDA-registered 503A or 503B compounding pharmacies without naming a facility. For a compounded product, where sterility and dosing accuracy live entirely with the compounder, that is the disclosure that matters most and it is absent.

Two prescribers are named, with real bios and no NPIs. A medical director, board-certified in family medicine and licensed in twenty-six named states, and a chief medical officer in internal medicine licensed in fifteen. Education and board certifications are published. Neither NPI is, so neither can be verified against the national registry — which is the difference between a credential and a claim, and the exact line The Edit crosses with a published NPI that resolves.

The corporate entity is pepti LLC at a Newark, Delaware suite that is a well-known registered-agent address rather than an operating site. Its certification seal resolves against the certifying body's own image host. Cancellation is any time, effective at the end of the cycle, with a pause of up to ninety days available and no proration.

The regulatory screen

The trading name and the legal entity both returned zero company-column matches in the FDA's live warning-letter index when we screened them in August 2026.¹² The screen carried a positive control — an unrelated telehealth seller with a letter on the record — which returned correctly, so the zero is a result and not a query that failed quietly.

The neighborhood is worth a sentence, because it cuts in Pepti's favor. A search on the stem of its name returns dozens of letters to peptide sellers. Pepti is not among them, and being absent from a list your own brand name puts you next to is a better result than it sounds.

Where it lands

If you want to try more than one NAD+ route without signing up to two companies, this is the only menu in the batch that lets you, and the prices are published, flat across doses and honestly labeled as monthly. That is real.

What you are buying is three unmeasured delivery routes, one of which — the capsule — is sold under a word that belongs to a different molecule with actual human data behind it. The unnamed pharmacy and the unverifiable prescribers are a worse disclosure record than The Edit's named pharmacy and resolving NPI, and the missing strength on the nasal rung means the dearest option here cannot be compared with anything. If your question is how to raise NAD+ for the least money on the most evidence, the answer is still an oral precursor — is nicotinamide riboside worth it and NMN vs NR work through it — and it is not sold here. Providers we do have a commercial relationship with are ranked and disclosed on our NAD+ rankings hub; where the rest of the market sits is on the NAD+ price index.